NHS ‘simply not ready’ for revolution in dementia care, experts warn | UK | News

Thousands of people with dementia miss the breakthroughs, because NHS is not just ready ”for a new age to diagnose and treat Alzheimer’s. A series of articles published in prestigious Lancet Medical Journal predict that the disease view will be significantly transformed by new drugs and blood tests in the coming years. However, 40 authors of the articles warned that the potential of “great innovations” will not take place without a rapid reform.

Britain’s leading dementia institutions said that the future was “full of hope last night and urged the government to ensure that people do not miss. Fiona Carragher, the chief policy and research assistant of the Alzheimer’s Association, said: “A new era for the treatment and diagnosis of Alzheimer’s disease has been confirmed by 40 leading experts in these Lancet newspapers. Research, the tempo of the new developments does not have a rapid and future.

“It is vital for the United Kingdom to ensure that people who are dementia are not left behind. We want to see better access to early diagnosis, so that people do not miss the narrow suitability window to take advantage of future treatments that may slow down Alzheimer’s disease.”

David Thomas, Head of Politics and Public Relations in Alzheimer Research UK, said: “Under ten years, the leading cause of dementia has doubled the number of experimental treatments for Alzheimer, and our understanding of illness progressed faster than ever.

“Nevertheless, these articles emphasize that scientific momentum alone is not enough. It shows great effects on how our health services are organized and underlines the need to create consensus among clinicians who have several options to present their patients for so long.

“For people affected by the demanti, it is a difficulty that governments and health services should be discussed.”

Almost a million people now live in Dementia in England – and this figure will rise due to the aging and increasing population of the country.

Alzheimer’s disease is the most common form of dementia, which constitutes approximately 60-80% of cases.

In recent years, Alzheimer’s research has seen major developments in his research, including the approval of the first drugs that have been proven to slow down symptoms and have discussed the underlying causes.

However, only two -thirds of people with dementia are diagnosed, ie up to one third, it misses early access to treatments when they are more likely to be effective.

The Alzheimer’s Association previously emphasized the lack of access to existing “gold standard” tests, such as lumbar punctions and pet scans, which only received one of 50 patients.

The main attempts of finding a reliable blood test that can improve diagnostic rates are continuing. British patients are now being hired to try a test that measures the levels of a protein called P-TU217 and measures the expected results within three years.

Experts in Lancet estimate that blood tests will “lead to a new diagnostic circuit and bring major changes in worldwide health systems”.

Professor Giovanni Frison, a clinical neurologist at the University of Geneva in Switzerland, said that social change is needed to enable existing and future Alzheimer’s patients to fully benefit from scientific progress.

“Blood tests, biological drugs for Alzheimer’s disease and prevention interventions pushes care into a completely new and exciting area.

“However, the old needs of the patients will not disappear. On the contrary, more general practitioners and dementia specialists will need to dominate sophisticated diagnosis imaging and laboratory tools in the care and treatment of behavioral disorders, and less eye -catching but stable progress made in the last few decades of psychosocial care.

“A harmonious social effort in this direction will enable our existing and future patients to fully benefit from the potential of scientific and technological progress.”

Prof Frisoni said that the understanding of Alzheimer’s disease will “change radically in the near future”.

“As in all medical revolutions, it is not something that happens overnight, but it will take place over the years, but the road has been clearly taken and there is no way to return,” he said.

The analysis of the experts found that the drugs rejected for the use of NHS for the use of NHS to justify the costs of the experts found that Laceemab and Hardemab – Alzheimer decided to slow down as effective as treatments for other cases such as cancer, rheumatoid arthritis and multipler.

For example, they found that Lecemab was more effective for MS than the drug of Ocelizumab in Alzheimer’s treatment. The cost of Ocrelizumab is three times in Laceemab and is available in NHS.

Prof Frison said: “Of course, other conditions are different, different from multiple sclerosis Alzheimer’s disease. However, there are some dimensions that we can use as an anchor to compare these drugs.

“When you do this exercise, you realize that these drugs are not more toxic for Alzheimer’s, that they are not less effective, it is not more expensive.

“The potential size of the beneficiaries that are really different. This real difference. Discussion moves from a clinical debate to a political debate. Does society want to invest?”

According to Alzheimer Society, one in three people born in England today will develop dementia throughout their lives. Approximately 1.4 million people in the UK is expected to live with a situation until 2040.

Dr. Richard Oakley, the Research and Innovation Director of the Charitable Organization, said that the series of articles marked the beginning of a new era in the diagnosis and treatment of Alzheimer’s disease ”.

However, he added: “The painful truth is that NHS is not ready and does not keep up with science.

“It is vital for people with the British government to keep their eyes on the ball to prevent them from being left behind. We want to see better access to early diagnosis, so that people do not miss the narrow suitability window to take advantage of the treatments that may slow down Alzheimer’s disease.

“Preparing for future treatments will take the community of researchers, clinicians and decision -makers.”